Hemophilia A With Inhibitor Clinical Trials

30 clinical trials for Hemophilia A With Inhibitor across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors — RECRUITING · PHASE4
• Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) — RECRUITING · PHASE4
• ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor — RECRUITING · PHASE4
• Pharmacokinetic-guided Dosing of Emicizumab — RECRUITING · PHASE4
• Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction — NOT_YET_RECRUITING · PHASE4
• Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors — COMPLETED · PHASE1
• Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors — ACTIVE_NOT_RECRUITING · PHASE3
• ATHN 7: Hemophilia Natural History Study — COMPLETED
• The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial — TERMINATED · PHASE3
• rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A — COMPLETED
• An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families — COMPLETED
• SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment — COMPLETED · PHASE1
• Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem — COMPLETED
• A Phase I of SS109 in Hemophilia A or and B With Inhibitors — COMPLETED · PHASE1
• The Hemophilia Inhibitor Eradication Trial — TERMINATED · PHASE3
• ATHN 8: Previously Untreated Patients (PUPs) Matter Study — COMPLETED
• Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors — COMPLETED · PHASE1
• A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab — ACTIVE_NOT_RECRUITING · PHASE4
• Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven — COMPLETED
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders — TERMINATED · PHASE1
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B — TERMINATED · PHASE3
• A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip — OTHER · PHASE2
• Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B — COMPLETED · PHASE2
• Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia — COMPLETED · PHASE1
• The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors — OTHER
• Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. — OTHER · PHASE1
• INdividualized ITI Based on Fviii(ATE) Protection by VWF — TERMINATED · PHASE4
• Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China — OTHER · PHASE4
• Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors — OTHER
• Hemophilia Inhibitor Genetics Study (HIGS) — COMPLETED

Refine this search